Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Second MenC booster age study in Dutch adolescents
NL-OMON39602Active, not recruiting
- Sponsor
- National Institute for Public Health and the Environment
- Start
- Oct 2011
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Open-label trial of Meningococcal group C polysaccharide conjugate vaccine in meningococcal group C disease and meningococcal disease (3 cohorts), sponsored by National Institute for Public Health and the Environment. Primary endpoints: Serum bactericidal antibody levels at baseline, 1 month, and 1 year and Long-term serum bactericidal antibody persistence at 3 years. Started Oct 2011; status: active, not recruiting.
02
Drugs
Meningococcal group C polysaccharide conjugate vaccine
03
Conditions
meningococcal group C diseasemeningococcal disease
Beyond the preview
Go deeper on NL-OMON39602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39602.